The PD-1 Pathway in Allergy: A Balancing Act

In recent decades, the global prevalence of allergic diseases has increased markedly. This trend underscores the urgent necessity for a deeper understanding of the immunoregulatory networks governing hypersensitivity responses. Controlling the balance between T cell activation, tolerance, and tissue damage is central to maintaining immune homeostasis. Specifically, the PD-1 pathway in allergy has emerged as a critical checkpoint that manages these complex interactions.

Differential Roles of PD-L1 and PD-L2

The programmed cell death 1 (PD-1) receptor interacts with two primary ligands, PD-L1 and PD-L2. Although they share the same receptor, they exert significantly different effects on the immune system. PD-L1 mostly lowers type 1 immunity while simultaneously raising type 2 immunity, which can exacerbate allergic responses. Conversely, PD-L2 mostly promotes type 1 polarization and limits type 2 inflammation. Therefore, the relative expression of these ligands often dictates whether the immune system tilts toward chronic inflammation or successful resolution.

Impact of the PD-1 Pathway in Allergy Across Tissues

Research now extends beyond traditional asthma models to examine various allergic disorders. For instance, in allergic rhinitis and conjunctivitis, the tissue microenvironment plays a decisive role in signaling outcomes. Furthermore, dermatological disorders, food allergies, and systemic anaphylaxis all show evidence of PD-1 pathway involvement. Cellular origin and disease stage collectively influence whether PD-1 signaling facilitates or inhibits allergic inflammation. Consequently, a one-size-fits-all approach to immunotherapy may not be effective across different clinical presentations.

Therapeutic Potential and Clinical Risks

Targeting the PD-1 checkpoint offers promising therapeutic possibilities for immunomodulation in severe allergies. However, clinicians must carefully evaluate the associated risks. Since this pathway is vital for preventing autoimmunity and managing chronic infections, interfering with it could lead to unintended immune-mediated tissue damage. Future treatments may focus on selectively modulating specific ligands rather than blocking the entire pathway. This precision could help restore the delicate balance of immune tolerance without compromising overall safety.

Frequently Asked Questions

How does the PD-1 pathway influence asthma?

In asthma, the PD-1 pathway acts as a regulator of T-cell activation. PD-L1 deficiency often results in reduced airway hyperresponsiveness, while PD-L2 deficiency can significantly enhance the severity of lung inflammation.

Can PD-1 ligands be used as biomarkers for allergy severity?

Current research suggests that the expression levels of PD-L1 and PD-L2 on inflammatory cells may correlate with disease stages in allergic rhinitis and atopic dermatitis, though they are not yet standard clinical biomarkers.

What are the risks of targeting immune checkpoints in allergic patients?

The primary risk involves disrupting immune homeostasis, which might trigger autoimmune reactions or impair the body\'s ability to fight off chronic infections or tumors while attempting to suppress allergic inflammation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Mohamed AH et al. Involvement of the PD-1 pathway in the modulation of immune responses during allergic diseases. Inflamm Res. 2026 Apr 01. doi: undefined. PMID: 41917459.

Guzman-Ramirez et al. New Insights into the Role of PD-1 and Its Ligands in Allergic Disease. Int J Mol Sci. 2021 Nov; 22(21): 11898.

Akbari O et al. PD-L1 and PD-L2 in allergic diseases and asthma. Allergy. 2010; 65(10): 1205-1215.